Abstract
Purpose. To evaluate efficacy of angiogenesis inhibitor ranibizumab (Lucentis, Novartis, Switzerland) in treatment of choroidal neovascularization (CNV) in patients with chronic central serous chorioretinopathy (CSCR). Material and methods. The object of study was 11 patients (8 men and 3 women, 11 eyes) aged from 41 to 50 years with CNV on the background of chronic CSCR. All monitored patients underwent 3 consecutive “loading” intravitreal Lucentis injections is either 0.5 mg in 0.05 mL once a month. Results. After 3 months, all studied patients had complete obliteration of CNV. At the same time, the central retinal thickness was 224.5±13.3 µm, which did not differ significantly from norm (p<0.05). All 11 patients had stabilization of visual functions with average index of best corrected visual acuity of 0.9±0.13, exceeding the initial level by 0.15±0.04 (p<0.05), an increase in light sensitivity of central retinal zone was noted up to 22.41±1.2 dB. Conclusion. The data obtained allow us to state that timely use of angiogenesis inhibitor Lucentis in treatment of CNV in patients with the chronic CSCR is pathogenetically justified, effective and safe. Given frequency of recurrence, further studies of anti-VEGF therapy in treatment of chronic CSCR are needed to determine the need for repeated injections of anti-VEGF drugs. Key words: central serous chorioretinopathy, choroidal neovascularization, Lucentis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
